Emerging drug profile: cyclin-dependent kinase inhibitors
about
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationNew strategies in chronic lymphocytic leukemia: shifting treatment paradigmsCyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cellsEntering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.The history and future of targeting cyclin-dependent kinases in cancer therapy.The molecular mechanics of mixed lineage leukemia.Cyclin-Dependent Kinase Inhibitors as Anticancer TherapeuticsMultiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activityOverview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistancePro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?Biological functions of CDK5 and potential CDK5 targeted clinical treatments.Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human MacrophagesCell cycle regulation and anticancer drug discovery.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
P2860
Q26744087-CDA01D23-80CC-47F7-A2EA-23C8833B94B3Q26771165-600C7C60-A9AD-4BE1-9311-1D65F188D3FFQ26828496-E5ECE9C3-7D34-46BF-A98F-E65DC534D5DDQ34027454-A1040116-2995-4E35-B3E7-FFBE7EDE4131Q34172063-E40CDCE8-6BD2-43FA-9AE1-3AA294B149CAQ34301314-4CC37EF0-C696-4FF9-B5A4-FC915B54C5B9Q34460347-AA56D21A-784C-458D-8A08-762CCC67E48DQ34516051-DF9A5E97-8D68-4B6D-8AAF-95F663801905Q36186117-BE8B478B-DB73-43A7-8D71-54A658FD7388Q37063908-B00BD79D-83E0-4043-9ABD-9ECFEE669259Q38175443-55212CD8-F61E-4F59-80AA-DE6602C9E1DFQ38544216-5B419AC9-8B9B-4FA2-9008-8A7F7A3A5D10Q38752310-64D38201-5FEF-49EA-BE68-5722E7D6970AQ38755091-D3C448DB-39D1-48F5-9197-C7F339AC6943Q38783064-4318D596-C7E7-4B12-9437-6BBC2C47B7E0Q38828117-E9601343-D042-4399-BB79-9F8179E3CB08Q38997714-07F59136-475D-496A-BA9A-AFAE65A10EF3Q39044576-2B84DEBC-B252-4344-AD0C-4A01C34BDEE0Q39080473-4F2C0FEF-C05B-43D2-8A08-298DE156A367Q39530544-81BC40D4-5C7A-47D6-82DD-3933453DA6F6Q49449591-02E5BEEF-2C71-4A28-8008-6727D339B373Q54322737-035DA6E3-6B0F-4BA6-8D4A-3CEFE187F8C8
P2860
Emerging drug profile: cyclin-dependent kinase inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drug profile: cyclin-dependent kinase inhibitors
@en
Emerging drug profile: cyclin-dependent kinase inhibitors.
@nl
type
label
Emerging drug profile: cyclin-dependent kinase inhibitors
@en
Emerging drug profile: cyclin-dependent kinase inhibitors.
@nl
prefLabel
Emerging drug profile: cyclin-dependent kinase inhibitors
@en
Emerging drug profile: cyclin-dependent kinase inhibitors.
@nl
P2860
P1433
P1476
Emerging drug profile: cyclin-dependent kinase inhibitors
@en
P2093
James S Blachly
P2860
P304
P356
10.3109/10428194.2013.783911
P50
P577
2013-07-29T00:00:00Z